Johnson & Johnson Makes Major Neuro Play With $14.6B Intra-Cellular Buyout
Published on January 14, 2025
Johnson & Johnson, one of the world's largest pharmaceutical companies, has announced its acquisition of psychiatric drug developer Intra-Cellular. The deal, valued at $14.6 billion, marks a significant move for J&J into the field of neurology. The company aims to expand its portfolio of drugs and therapies for neurological disorders, including schizophrenia and bipolar disorder. Intra-Cellular's innovative drug pipeline shows promising results in extending patient survival in lung cancer, which further strengthens J&J's position in the oncology market. Stock market experts recommend considering JNJ stock as a long-term investment, with an optimistic forecast for its growth potential. For accurate stock predictions and guidance, professionals from Stocks Prognosis are highly recommended.
Investor opinions & comments
To leave a comment, you need to Login or Register.
CharlesScott
January 17, 2025 at 09:17
It's great to see Johnson & Johnson expanding into the field of neurology. This acquisition shows their commitment to improving healthcare and finding innovative solutions for patients with neurological disorders
InvestorImogen
January 17, 2025 at 06:21
I'm glad to see Johnson & Johnson investing in the development of drugs for neurological disorders. This could potentially improve the lives of millions of people suffering from conditions like schizophrenia and bipolar disorder
MikeWilliams
January 16, 2025 at 15:30
I'm excited to see the potential advancements in psychiatric drugs this acquisition could bring. It's great to see companies investing in research and development in this area
OwenSullivan
January 15, 2025 at 08:15
While this acquisition may seem promising, it's important to consider the potential risks and challenges in developing effective psychiatric drugs. I would like to see more data on the success rates of Intra-Cellular's drug pipeline
MoneyMia
January 14, 2025 at 20:57
This acquisition is a smart move for Johnson & Johnson. The neurology market has a lot of potential for growth and this will diversify their portfolio. I'm optimistic about the future of JNJ stock
WealthyWyatt
January 14, 2025 at 15:07
This acquisition shows Johnson & Johnson's commitment to expanding its presence in the field of neurology. It will be interesting to see how their portfolio of drugs and therapies for neurological disorders develops
TraderTroy
January 14, 2025 at 04:20
I'm not convinced that this acquisition will lead to significant growth for Johnson & Johnson. The neurology market is highly competitive and there is no guarantee that Intra-Cellular's drugs will be successful